Message #47 From:
NewsBot Date: December 21, 2007 07:00:04 AM
Neoprobe Announces Extension of Marketing Agreement with Ethicon Endo-Surgery, Inc
Neoprobe Corporation (OTCBB:NEOP),
a diversified developer of innovative oncology and cardiovascular
surgical and diagnostic products, announced the extension of its
marketing and distribution agreement with Cincinnati-based Ethicon
Endo-Surgery, Inc.
The amendment extends the rights for Ethicon Endo-Surgery to promote and
sell the neo2000®
gamma detection systems for assisting in cancer diagnosis through the
end of 2013.
“Our arrangement with Ethicon Endo-Surgery has
been integral in positioning Neoprobe as the market leader in the
handheld gamma detection market,” said David
Bupp, Neoprobe’s President and CEO. “We
are excited about continuing to bring innovation to the lymphatic
mapping market through partnering with the leading provider of surgical
devices.”
Neoprobe’s gamma detection systems are
currently used in lymphatic mapping for determining various stages of
cancer. The system utilizes a radioactive tracing agent, which is
injected directly into the tumor site. The agent then follows the same
flow along the lymphatic system that a tumor would follow if it
metastasized or spread. The operative surgeon can then track this flow
with a special probe identifying key lymph nodes along the path to be
tested for the presence of cancer.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and
improving patient outcome by meeting the critical intraoperative
diagnostic information needs of physicians and therapeutic treatment
needs of patients. Neoprobe currently markets the neo2000®
line of gamma detection systems that are widely used by cancer surgeons
and is commercializing the Quantix®
line of blood flow measurement products developed by its subsidiary,
Cardiosonix Ltd. In addition, Neoprobe holds significant interests in
the development of related biomedical systems and radiopharmaceutical
agents including Lymphoseek®
and RIGScan® CR.
Neoprobe’s subsidiary, Cira Biosciences,
Inc., is also advancing a patient-specific cellular therapy technology
platform called ACT. Neoprobe’s strategy is
to deliver superior growth and shareholder return by maximizing its
strong position in gamma detection technologies and diversifying into
new, synergistic biomedical markets through continued investment and
selective acquisitions. www.neoprobe.com
Neoprobe Corporation Brent Larson, 614-822-2330 Vice
President / CFO or The Trout Group Tim
Ryan, 646-378-2924
